Crucell Terug naar discussie overzicht

Draadje vogelgriep

1. [verwijderd] 18 september 2006 21:15

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Ja oudje,je hebt weleens meer aangegeven dat je het niet zo hoog op hebt met het vogelgriep gebeuren,en dit vooral wat de financiele kant betreft,daarintegen moet een bedrijf als Crucell wel degelijk zijn bijdrage leveren wil het uberhaubt meetellen in de wetenschappelijke waardering,zo ook natuurlijk onderzoek HIV, ook een puur samenwerkende doelstelling,die ten allereerste gaat om de bevrijding van deze vreselijke ziekte.
   Met alle respect maar dit maak ik op uit jouw reactie.
   
   mvg rb
2. [verwijderd] 18 september 2006 21:22

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Ja, Snorremans, je hebt helemaal gelijk, joh. Natuurlijk moeten we met z'n allen die vogelgriep overleven. Maar ik wil alleen maar zeggen, dat het minstens net zo veel kost als het oplevert. De meesten zitten hier toch aan zwaar geld verdienen te denken.
   
   Met HIV is het toch een iets ander verhaal. Men komt toch stapje voor stapje verder. Merck kan, met gebruikmaking van PerC6, wellicht rond 2010/2011 met iets goeds komen.
3. [verwijderd] 20 september 2006 19:13

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   www.agriholland.nl/nieuws/artikel.htm...
4. [verwijderd] 21 september 2006 20:38

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   20 September 2006
   U.S. Global Pandemic Assistance Nears $400 Million
   International pandemic partnership enters second year
   By Charlene Porter
   Washington File Staff Writer
   
   Washington – The United States is boosting its contributions to the international effort to combat avian and pandemic influenza, bringing U.S. contributions over the past year to $392 million, according to a September 20 announcement by U.S. Under Secretary for Democracy and Global Affairs Paula Dobriansky.
   The announcement was made in New York in conjunction with the U.N. General Assembly session one year after President Bush had announced formation of the International Partnership on Avian and Pandemic Influenza (IPAPI) at the same forum. (See related article.)
   “We need only to look back to the SARS outbreak of three years ago,” Dobriansky said, “to understand that the social, economic and political impacts of a virulent flu pandemic could be devastating.”
   In a statement from Washington, U.S. Health and Human Services Secretary Mike Leavitt also endorsed the early voluntary implementation of the international regulations, and cited other examples of cooperation between the United States and the World Health Organization (WHO) in the global effort against avian and pandemic influenza.
   "We are funding the Specimen Transport Fund, managed by the Secretariat of the World Health Organization," Leavitt's statement said. "It is a key innovation in getting samples from affected countries in a timely and secure fashion."
   Ninety-three nations have joined IPAPI, along with 20 international organizations.
   Dr. David Nabarro, senior U.N. coordinator for avian and human influenza, UNICEF Director Ann Venneman and Dr. David Heymann, director of the communicable diseases cluster at the WHO, joined Dobriansky at the press conference.
   INTERNATIONAL REGULATIONS
   “The World Health Assembly [WHA] has requested that WHO begin implementation of the revised International Health Regulations,” Heymann said, “this year for avian influenza and next year for the framework that will involve other diseases as well.”
   The WHA unanimously adopted the revised regulations in May 2005, and they are scheduled to enter into force in June 2007. (See related article.)
   The broadened purpose, according to WHO, is to "prevent, protect against, control and provide a public health response to the international spread of disease and which avoid unnecessary interference with international traffic and trade."
   Heymann said a group of experts will meet for the first time September 25, forming a task force on avian influenza as part of the international health regulation framework.
   The group will review evidence bases on containing outbreaks, stockpiling, global vaccine pandemic planning, and virus information sharing through WHO and other databases, he said.
   “WHO is very pleased to be a partner in this larger partnership dealing with preparedness for avian influenza,” he said.
   NATIONAL PLANS
   IPAPI was formed in response to concerns from international health experts that a highly pathogenic avian influenza virus that appeared in Southeast Asia in late 2003 has the potential to trigger a human health pandemic.
   The H5N1 virus now has been detected in wild birds or domestic poultry in more than 50 nations.
   Human cases of the disease have appeared in 10 countries, causing 144 deaths. In most cases, individual exposure to the disease has been traced to direct contact with sick poultry.
   Health authorities warn that if the H5N1 virus were to mutate to become contagious among humans, a global pandemic of human influenza could result, with severe effects on human health, social structures and economic activity.
   With the support of IPAPI over the last year, Dobriansky said, more than 175 nations have national plans for combating avian and pandemic influenza.
   Animal and human health authorities in only 40 nations had crafted such plans prior to the formation of IPAPI, according to the U.S. State Department’s Avian Influenza Action Group.
   CONTROLLING DISEASE
   In collaboration with international organizations and through its own health and aid agencies, the United States is providing support and technical assistance to dozens of nations to better enable them to contain and control the disease in animal and human populations. (See related article.)
   The U.S. departments of Agriculture, Health and Human Services, Interior and others have deployed scientists, veterinarians, public health experts and emergency response teams to affected and high-risk countries to assist in dealing with actual outbreaks or to help develop plans for potential outbreaks.
   U.S. assistance also is being used to help upgrade diagnostic and laboratory capabilities in vulnerable countries, and train animal and human health specialists who will be responsible for responding to outbreaks, according to a U.S. State Department September 20 fact sheet. (See related article.)
   The U.S. Agency for International Development (USAID) has shipped about 93,000 personal protective equipment kits to 66 countries for use by responders in the field in 2006, according to the fact sheet.
   That effort continues as USAID works to build a stockpile of 1.5 million personal protective equipment kits, 100 lab kits and 15,000 decontamination kits for deployment as necessary in the event of future avian influenza outbreaks.
   
   (The Washington File is a product of the Bureau of International Information Programs, U.S. Department of State. Web site: usinfo.state.gov)
   usinfo.state.gov/xarchives/display.ht...
5. [verwijderd] 22 september 2006 09:23

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Sanofi Pasteur throws $30m into Canadian vaccine plant
   
   By Gregory Roumeliotis
   
   Related News
   
   GSK's thirst for adjuvants grows
   FDA hits sanofi pasteur with warning letter
   Sanofi Pasteur to license novel vaccine adjuvant
   New Sanofi plant increases vaccine production
   Sanofi awarded flu vaccine development contract
   
   
   21/09/2006 - French vaccine giant Sanofi Pasteur has announced a $30m (€23.5m) capital expansion project at its Connaught Campus in Toronto, significantly increasing manufacturing capacity for its popular acellular pertussis and polio vaccines.
   
   With this expansion the company is seeking to secure supply in Canada and around the world for its Pentacel and Quadracel vaccine combinations, now licensed in 52 countries in Europe, Asia and the Americas.
   Pentacel, a combination vaccine which protects children against five diseases - tetanus, diphtheria, polio, whooping cough and haemophilus influenzae type b - is the leading children's vaccine in Canada for these five major diseases, used in infants of 2,4,6 and 18 months, while the Quadracel combination is used in children at 4 to 6 years.
   
   According to Sanofi Pasteur, these vaccines have been the cornerstone of Canada's infant immunisation programme, have had a dramatic impact on rates of whooping cough and all but eliminated Haemophilus Influenzae type b disease, while continuing to provide control of diphtheria, tetanus and polio.
   
   Details of the expansion were not provided but it is understood that over 1,100 employees research, develop, manufacture and market vaccines to Canada and the world from the company's north Toronto site.
   
   On site to celebrate the capital expansion was Ontario Premier and Minister of Research and Innovation Dalton McGuinty and Mark Lievonen, Sanofi Pasteur president.
   
   
6. [verwijderd] 22 september 2006 20:31

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   22 september 2006
   
   WHO RANKS BIRD FLU AS TOP HEALTH TREATH
   BIRD FLU remains the number one danger facing global public health, the World Health Organisation warned as a five-day conference on issues facing the western Pacific region wrapped up today.
   
   The WHO Western Pacific Region's 57th annual meeting wound to a close in Auckland amid warnings over avian influenza and rising lifestyle-related diseases such as obesity and cancer.
   
   Earlier this week, WHO acting regional director for the western Pacific Dr Richard Nesbit urged member country delegates to do more to prepare for an outbreak of birdflu, saying no nation would be immune.
   
   The group was also told WHO lacked about half of the funds needed to help countries prepare for and fight bird flu.
   
   WHO spokesman Peter Cordingley said many countries did not have the money or resources to implement full emergency plans.
   
   He said a potential pandemic could spread quickly to remote nations due to the speed of modern transport.
   
   "It will travel at the speed of a 747 jet,'' Mr Cordingley said.
   
   "We're asking everybody to take precautions.''
   
   Dr Nesbit said the meeting had also recognised lifestyle diseases such as obesity, cancer and problems associated with excessive alcohol consumption also had to be "urgently addressed''.
   
   Member countries undertook to step up their defences against threats such as birdflu and non-communicable diseases.
   
   The meeting endorsed a regional strategy designed to stem the exodus of healthcare workers from poorer countries in the region to more affluent nations.
   
   The gathering of senior health officials heard that, unchecked, the migration could push some of the region's public health systems to the brink of collapse.
   
   Other issues examined included universal access to HIV/Aids treatment, prevention and control of tuberculosis, and program updates on measles elimination, hepatitis B control and polio eradication, as well as tobacco control, mental health and environmental health.
   
   "We had a very broad agenda this year,'' Dr Nesbit said.
   
   "I believe that it is a fair reflection of the magnitude of the health problems facing the region and of the determination of our member states to tackle those issues.''
   
   www.news.com.au/couriermail/story/0,,20456932-1702,00.html?from=rss
   
7. [verwijderd] 22 september 2006 20:54

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Speaker details dangers of avian flu
   'We will see bodies pile up,' physician cautions
   
   By John Mitchell, jmitchell@VenturaCountyStar.com
   September 22, 2006
   
   At the end of Dr. Michael Osterholm's presentation on an avian influenza pandemic to members and guests of the World Affairs Council of Ventura County, Jay Berger, the council's executive director, took the microphone.
   
   He thanked Osterholm for his talk, then added, "even though you scared the living bejeebies out of me."
   
   
   
   
   
   Osterholm, director of the Center for Infectious Disease Research and Policy at the University of Minnesota and associate director of the Department of Homeland Security's National Center for Food Protection and Defense, said a potentially deadly bird flu pandemic is coming.
   
   He doesn't know when or where it will land in the United States, but, he said, a serious effort should be mounted "right now" by federal, state and local agencies to prepare for it.
   
   "If the pandemic is caused by H5N1, the avian influenza virus strain currently circulating in Asia, it could kill as many as 1.9 million Americans and infect 30 to 60 percent of the population," he said, adding that H5N1 is the most powerful influenza virus detected in modern history.
   
   Osterholm told the approximately 150 people at Wednesday's dinner meeting in Westlake Village that H5N1 has many similarities to the H1N1 virus.
   
   That virus killed an estimated 50 million people worldwide in 1918-19, the National Institutes of Health says on its Web site. A report on a Stanford University Web site says about 675,000 of them were Americans.
   
   Currently, H5N1 can be passed from bird to animal to human, and the virus could evolve to a stage where it could be passed from human to human, Osterholm said.
   
   According to the World Health Organization, bird flu has infected 247 people since 2003 and killed at least 144 of them. United Nations and Nigerian health officials suspect Nigeria may be the first country in Africa to have bird flu casualties. A search is being conducted in areas where it is known that chickens live with families.
   
   For people who doubt the looming danger, Osterholm said, "I wouldn't bet my family's life that it's not going to happen."
   
   Currently, there is no bird flu vaccine, he said.
   
   "We're still using 1950s vaccine," he said. "Over the decades there has been only one major modification to it. And H5N1 vaccine research results generally have been disappointing.
   
   "We may be years away from a modern influenza vaccine with enough production capacity for the world."
   
   When the pandemic hits, what will it be like?
   
   "Imagine a 12-to-18-month global blizzard," he said.
   
   Osterholm said areas to be concerned about include worker and patient protection (from the virus), and medical devices and staffing.
   
   Even the dead will be contagious.
   
   "Corpse management, the handling of the dead and how we grieve, will be very important," he said.
   
   "We will see bodies pile up right here in Ventura County. You've got to start planning, locally, now."
   
   Individuals and families should stockpile a six- to 12-week supply of food and water in their homes, he said. Business and education areas must prepare to protect employees and students.
   
   Planning should cover quarantine, border closings, social distancing (such as working from home instead of the office), infection control and respiratory protection, Osterholm said.
   
   Also, the pharmaceutical industry should be encouraged to increase its medication inventory in pharmacies and other outlets.
   
   Otherwise, monthly prescriptions will not be filled.
   
   "There are many areas to be considered," he said.
   
   Before Osterholm's talk, Ventura County Sheriff Bob Brooks and Ventura County Health Officer Dr. Robert Levin addressed the pandemic issue.
   
   Brooks said his department is working with public health in planning for pandemic influenza, a smallpox outbreak, a chemical attack and a nuclear attack.
   
   The department also participates in the Public Health Bio Medical Advisory Council and in mass evacuation planning.
   
   It is also dealing with issues of providing security at vaccination sites; responding to public disorders because of a breakdown in the distribution of food or other critical shortage. Also, plans are being made on how to provide public services despite losing 30 percent to 40 percent of personnel to the flu virus.
   
   Levin said a critical part of his department's planning is to tell the public things may collapse around them.
   
   "That is where they come in," he said. "The antidote for closed grocery stores is a full pantry of dry and canned goods at home. The treatment for a power shortage is flashlights and radios that crank up or run on batteries."
   
   Levin recommended going to an American Red Cross Web site that has information on preparing for a disaster, which is at
   
8. [verwijderd] 22 september 2006 21:29

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Topic: Should WHO chief save face or save lives?
   Posted: 12 Sep 2006 at 10:42pm
   Should WHO chief save face or save lives?
   By SIMON LEE
   
   Hong Kong _ Yesterday was the closing date for candidates to lead the World Health Organisation. Let's hope that when elections are held in November, they find someone with the character to tackle both new transnational health threats such as avian flu, and persistent killers such as diarrhoea, TB, malaria and Aids. Unfortunately, at least one candidate has already shown signs that she might not have what it takes.
   
   One of the favourites to replace the late Dr Lee Jong Wook, who died suddenly in May, is China's candidate Margaret Chan. Currently in charge of the WHO's response to avian flu, she was also director of health in Hong Kong from 1994 to 2003, a period that coincided with the emergence of both avian flu and severe acute respiratory syndrome or Sars.
   
   As avian flu marches up the global political agenda, her experience in these two roles should make her a shoo-in. After all, the World Bank has just announced that Indonesia's economy has already been affected by bird flu and the WHO is the only agency with the skills and mandate to coordinate the response to this kind of pandemic health threat. What could be better than a leader who already has a track record of dealing with them?
   
   The problem is Dr Chan's past actions show her to be more concerned with saving face than saving lives, an unsuitable candidate for a position that requires honesty, accountability and genuine leadership.
   
   Take the Sars outbreak of 2003. Dr Chan was then chief health adviser to the Hong Kong government and responsible for determining strategy. Although the outbreak came to an end fairly swiftly, it killed a total of 298 people in Hong Kong.
   
   A subsequent enquiry by the Hong Kong legislature concluded that Dr Chan's response to the Sars outbreak was unsatisfactory, condemning her for not attaching sufficient importance to soft intelligence on the epidemic and not taking account of the heavy passenger flow between Guangdong and Hong Kong.
   
   If Dr Chan had announced the epidemic in Guangdong in the two months before the outbreak arrived in Hong Kong, hospitals would have had time to prepare. Instead, Hong Kong's hospitals acted like an incubator for the disease before it spread out into the community.
   
   More egregiously, Dr Chan spent the vital early days of the outbreak wrangling with the WHO over its choice of the name for the disease: Sars.
   
   This choice was coincidentally similar to the official abbreviation for Hong Kong, the Special Administrative Region (SAR). Instead of immediately setting in train the necessary procedures to tackle the outbreak, Dr Chan wasted time trying to save China's face by protesting against the name Sars.
   
   Without this delay many lives could have been saved.
   
   Dr Chan's handling of avian flu in Hong Kong was equally inept. When the H5N1 virus was first identified in 1997, nobody knew if it could spread to humans. Dr Chan sought to reassure a jittery public by declaring, ''I eat chicken every day.''
   
   However, as it emerged that poultry were dying in great quantities, the Department of Food Hygiene decided to intervene before a crisis developed. Even though Dr Chan had famously told everyone to carry on eating chicken, the Hong Kong government slaughtered approximately 1.6 million and banned all chicken imports.
   
   So it was actually the head of the Department of Food Hygiene who took the tough decision that risked embarrassing Beijing. Dr Chan, meanwhile, was more concerned about saving her boss's face than with protecting public health.
   
   China is at the centre of a number of emerging health threats. In addition to avian flu, for which honesty and openness from China will be absolutely vital if a devastating global pandemic is to be prevented, China has a burgeoning Aids problem which threatens millions of people. However, censorship and the restriction of free speech has meant that these two diseases have either been underplayed or officially disavowed in China, denying people the knowledge needed to protect themselves.
   
   If Dr Chan held the top job at the WHO, China would effectively have carte blanche to continue the deceptions and ignorance on which infectious diseases such as HIV/Aids and avian flu thrive.
   
   Avian flu is perhaps the biggest communicable disease threat facing the world. To defeat it and to defeat the many other existing diseases and emerging threats will require accountability and honesty from the WHO, the only agency that has the ability to coordinate action on a global scale.
   
   Dr Chan's past actions in dealing with avian flu have shown her to be more concerned with politics than public health. WHO member states could save face now by electing someone else.
   
   Simon Lee is a Hong Kong-based analyst and a columnist for ''Apple Daily''.
   
   
   
9. [verwijderd] 24 september 2006 22:28

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Sun Sep 24, 6:47 AM ET
   
   
   JAKARTA (AFP) - A nine-year-old boy has been confirmed as Indonesia's 51st human bird flu fatality, a health ministry official said.
   
   ADVERTISEMENT
   
   
   
   
   The boy died on September 22 and test results from two laboratories confirmed he was infected with the H5N1 virus, a doctor on duty at the national bird flu center in Jakarta told AFP Sunday.
   
   He identified the laboratories as the ministry of health's laboratory and that of the US Naval Medical Research Unit (Namru).
   
   The boy died shortly after he was admitted to the Sulianti Saroso hospital, the capital's main center for bird flu treatment, said the doctor, who declined to be named.
   
   The latest death brought the overall toll in Indonesia from H5N1 to 51, the highest reported anywhere in the world.
   
   Tests from two laboratories are required for the World Health Organization to count the fatality in its official toll.
   
   The boy, who came from Pondok Pinang in South Jakarta spent two days at a police hospital before he was moved to Sulianti Saroso, the doctor said.
   
   He could not immediately provide more details, including whether the victim had come into contact with sick poultry, the usual method of transmission of the virus.
   
   But he said the boy's family had informed doctors that the boy had already been under high fever for about a week before he was admitted to hospital.
   
   Indonesia's death toll from bird flu has been steadily rising as the virus has marched across the archipelago nation, spreading to 29 of its 33 provinces.
   
   While the virus does not spread easily among people, the chance of a mutation that would allow it to do so is heightened as more humans catch it from infected birds.
   
   Scientists fear that if this occurs, a global flu pandemic with a massive death toll could result
   
10. [verwijderd] 25 september 2006 12:23

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    New plants not the answer to flu pandemic says study
    
    By Gregory Roumeliotis
    
    MedImmune in $250m biologics plant expansion
    Embrex helps Chinese vaccine producer not to lay an egg
    Consumables and contract manufacturing the drivers of the bioprocessing industry
    North Carolina lands $600m Novartis vaccine plan
    New manufacturing process can double HIV vaccine production
    Vaccine manufacturers in $1bn bird flu bonanza
    
    
    25/09/2006 - Moving from egg-based production of vaccines to the use of cell-culture technologies in existing manufacturing plants is cheaper and quicker than building new facilities to handle a flu pandemic within the next five years, new research suggests.
    
    A study led by University of Michigan professor of chemical and biomedical engineering Henry Wang and doctoral student Lyle Lash found that training personnel to make cell culture vaccines in existing facilities is the only way to make enough doses to cover the US in a short time without requiring huge capital investments to build new dedicated flu vaccine cell culture facilities.
    At present, most flu vaccines are made from hen eggs, but in light of a possible pandemic and ongoing shortages even during normal flu season, the government and private corporations like Novartis and MedImmune have been scrambling for new and faster ways to make a flu vaccine.
    
    The researchers examined the economics of producing egg versus cell culture vaccines and identified time and capacity as critical factors in responding to a pandemic.
    
    It obviously takes much longer to compile millions of hen eggs than it would to grow up existing cell lines from frozen vials, and while cell culture has a lower yield than egg culture, there is more existing capacity for cell culture than for inoculating and processing eggs.
    
    “Based on existing dosages, we would have enough doses in about three to four months to cover the US with the system we propose,” said Lash.
    
    “Currently, it would take six months to make 250m to 300m doses of pandemic flu vaccine for the US, what we are proposing could make 600m doses in four months.”
    
    According to Lash, there are about 15 facilities in the country that make protein products from mammalian cell cultures where staff could be trained to make flu vaccines using cell cultures.
    
    Indeed, many drug firms have been investing in developing cell culture flu vaccines due to government funding and the increase in price of the seasonal flu vaccine.
    
    Before fears of an avian influenza pandemic and a vaccine shortage took hold, one dose cost about $1.6 (€1.2), whereas now each dose commands $8 to $10.
    
    Lash pointed out that this profit margin is still low compared to the profits that existing cell culture facilities can make off their protein products.
    
    However, there is a cost associated with switching to cell culture, stemming from the downtime necessary to train personnel and to run test batches.
    
    Yet with research into different processes for purifying the vaccine, it would not be necessary to renovate facilities.
    
    Nevertheless, Lash said there must be some type of government funding to subsidise companies for lost production time due to training staff.
    
    Researchers envision a sort of national guard approach, with staff trained and on standby to respond to an pandemic.
    
    The study received a warm reception at the American Chemical Society National Meeting earlier this month.
    
    
12. [verwijderd] 25 september 2006 19:01

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    
    
    
    
    Press Release Source: eGene, Inc.
    
    eGene Completes Successful Study of Rapid and Inexpensive Detection of H5N1 Avian Flu Strain with Primers from Genome Institute of Singapore
    Monday September 25, 12:03 pm ET
    
    IRVINE, Calif.--(BUSINESS WIRE)--eGene, Inc. (OTCBB:EGEI - News), a leading bioengineering company and developer of a compact and automated digital genetic analyzer, today announced that it had recently, using H5N1 avian influenza primers provided by the Genome Institute of Singapore, completed a successful application study that demonstrated that eGene's HDA-GT12 Genetic Analyzer can successfully detect H5N1 avian influenza to as few as 10 viral RNA copies.
    ADVERTISEMENT
    
    
    The purpose of the study was to analyze the viability of developing a rapid, highly sensitive and low cost mass screening approach to detect the H5N1 influenza (bird flu) virus using a single step RT-PCR and automated HDA-GT12(TM) system.
    
    The resulting report indicated that the HDA system, in combination with the Institute's single step RT-PCR assay, is a simple and sensitive assay for H5N1 avian influenza detection that can detect as few as 10 copies of the viral RNA. Furthermore, the sample analysis rate in the HDA system is approximately two samples per minute, so a total of 96 samples in a 96-well plate can be analyzed in 50 minutes. The calculated test cost of HDA-GT12 system is less than a dollar per sample (US), making it ideal for mass screening. The eGene system can also be used as a portable H5N1 avian influenza detection tool in field operations, since collected digital data and analyzed results can be stored and transferred in electronic format.
    
    "The spread of avian influenza is still a major concern in the world," said Dr. Ming S. Liu, chief executive officer of eGene. "Continuous outbreaks of this highly pathogenic strain could unleash a pandemic that would have the potential to be as deadly to the population as the epidemic strain of influenza was in 1918. A fast, sensitive and low cost analysis to identify the contamination of the viral RNA in the poultry market can be one of the key factors to prevent the mass spread of the virus. We are pleased that eGene has been able to use the Genome Institute's H5N1 primers to develop a powerful and effective tool that may be applicable for bird flu screening."
    
    eGene developed the HDA-GT12(TM) (high-performance DNA analyzer for genotyping on 12 channels), currently in use at more than 100 hospitals and research centers worldwide. The system analyzes the genetic fingerprints of living organisms through microsatellites, AFLP and RFLP. It performs fast DNA sample screening and high-resolution DNA fragment analysis (2-5bp). The system also analyzes the quality and quantity of total RNA and cRNA, determines the efficiency of cRNA and cDNA amplification reactions, and ensures the quality of fragmented cRNA. The Company sells cartridges that are specific to the type of analysis to be performed. All data is then received in digital form for appropriate transmission and storage.
    
    About Genome Institute of Singapore
    
    The Genome Institute of Singapore (GIS) is a member of the Agency for Science, Technology and Research (A*STAR). A national initiative established in 2001, the research institute's mission is to be a world-class genomics institute and a centre for genomic discovery. GIS pursues the integration of technology, genetics and biology towards the goal of individualized medicine. The genomics infrastructure at GIS is utilized to train new scientific talent, to act as a bridge between academic and industrial research, and explore scientific questions of high impact. For its H5N1 avian influenza virus research, GIS has developed a set of proprietary PCR primers which have been used successfully worldwide (Brunei, Oman, Kuwait, UK, UAE, France, Vietnam and Indonesia). In 2005, the World Health Organization (WHO) Influenza Centre has tested the primers and found it to be highly specific and sensitive.
    
    About eGene, Inc.
    
    eGene, Inc. (www.egeneinc.com) focuses its core technologies of capillary electrophoresis, microfluidics, liquid handling and automation to develop and manufacture low-cost microfluidic, miniaturized digital analyzer systems, software and consumables for biological materials testing applications. These products detect, quantify, identify and characterize DNA and RNA at high rates of specificity and sensitivity while automating routine and non-routine laboratory and industrial procedures critical to product safety, development quality and productivity.
    
    This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors. The company undertakes no obligation to release publicly any revision, which may be made to reflect events or circumstances after the date hereof.
    
    Contact:
    Martin E. Janis & Company, Inc. for eGene, Inc.
    Beverly Jedynak, 312-943-1100, ext. 12
    bjedynak@janispr.com
    
    --------------------------------------------------------------------------------
    
    
13. [verwijderd] 27 september 2006 18:22

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Nastech awarded another grant to develop bird-flu drug
    
    by Emilie Reymond
    
    
    27/09/2006 - Nastech Pharmaceutical Company has received a new $1.9m (€1.5m) research grant from the US National Institutes of Health (NIH) to further develop its RNAi therapeutics to fight and prevent bird-flu.
    
    This windfall comes only a month after Nastech received a $400,000 Phase I research grant, also from the NIH, bringing the total awarded to Nastech by the organisation to $2.3m.
    
    The US-based pharma company said the latest grant will allow it to conduct further research in order to design and optimise small-interfering RNA (siRNA) therapeutics against seasonal and avian influenza viruses, testing in vivo activity of new siRNA delivery agents, as well as evaluating viral drug resistance mechanisms.
    
    “The success we have had in obtaining significant NIH funding for advancement of our siRNA therapeutic programme targeting influenza is credit to our strong scientific and development capabilities in this exciting new field,” said Steven Quay, chairman, president and CEO of Nastech.
    
    Indeed, siRNA therapeutics is an emerging field that could reach $185m by 2008, according to Front Line Strategic Consulting.
    
    The potential advantage of RNAi antiviral therapeutics is that siRNA can be targeted against the conserved region of the viral genome, meaning that an RNAi therapeutic would be effective against all strains of a virus, whether new or old.
    
    Using this method, Nastech is developing siRNA therapeutics that specifically target conserved regions of the influenza viral genome.
    
    Nastech's siRNA approach involves targeting one or more proteins critical for viral replication. By turning off the production of such proteins, the spread of infection is prevented or slowed.
    
    New and effective treatments are urgently needed for influenza, which infects approximately 5-15 per cent of the population in a typical year, resulting in 250,000 to 500,000 deaths according to the World Health Organisation (WHO).
    
    Furthermore, the ever-looming threat of a bird flu pandemic remains a major concern. Currently used prevention methods, like vaccines, have two key drawbacks. First, they are developed against individual known strains of flu and therefore may not be effective against new flu strains.
    
    Secondly, vaccines are produced using an extensive process requiring incubation in chicken eggs, thus vaccine against a new flu strain could take months or years to stockpile.
    
    Furthermore, antiviral medications currently approved to treat influenza, such as Roche's widely publicised Tamiflu, have the potential disadvantage of influenza virus strains becoming resistant to one or more of these medications.
    
    ----
    Related News
    
    Nastech pits intranasal formulation against Exubera
    Nastech awarded grant for siRNA therapeutics for flu
    Nastech secures manufacturing contract for new needle free osteoporosis drug
    Nastech develops non-injectable drug technology
    New plants not the answer to flu pandemic says study
    Roche hikes US Tamiflu production capacity
    Whole-virus formulation leads to dose-sparing H5N1 vaccine
    
    
14. [verwijderd] 27 september 2006 18:30

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    
    Monday, Sep 25, 2006
    WHO names experts who will advise when pandemic risk appears to be rising
    
    (CP) - The World Health Organization has announced the membership of the panel of experts it will turn to for advice if it believes the threat of a flu pandemic is mounting.
    The list of 20 or so international disease experts includes leading avian influenza expert Dr. Robert Webster of St. Jude's Research Hospital in Memphis, Tenn., Dr. Ab Osterhaus, a veterinary virologist at the Erasmus University in Rotterdam, and Dr. Nancy Cox, director of the influenza division at the U.S. Centers for Disease Control in Atlanta.
    
    Dr. Theresa Tam, director of the Public Health Agency of Canada's respiratory infections division, is also on the committee, which convened for the first time Monday in Geneva.
    
    The panel's mandate is to advise the director general of the WHO whenever it appears that there has been a change in the risk of a flu pandemic emerging. This group would review the evidence on patterns of infection and possible human-to-human spread and issue a recommendation on whether it believes it is time to change the pandemic staging level.
    
    The final decision on whether to move up - or down - the pandemic alert ladder rests with the director general.
    
    The WHO's pandemic phasing document is a six-step scale from no known pandemic threat (Phase 1) to a full-blown pandemic (Phase 6). The WHO's current assessment is that the world is in Phase 3 - a novel flu virus that has pandemic potential is causing sporadic human cases but only very limited human-to-human spread.
    
    Evidence of some clustering of cases of human infections of H5N1 avian flu virus in Indonesia and elsewhere this year has led to questions from some quarters about whether the WHO ought to raise the pandemic alert level to Phase 4, characterized as "evidence of increased human-to-human transmission.
    
    
    This new committee would be the body that would advise on that issue, if asked. But Monday's meeting was not called for that purpose, WHO officials have said. Instead, this meeting is a chance for the experts to hammer out a procedural framework for future deliberations.
    
    Membership is drawn from the six administrative regions of the World Health Organization: Africa, the Americas, Southeast Asia, Europe, the Eastern Mediterranean and the Western Pacific.
    
    Other members of the task force include Dr. Maria Zambon from Britain's public health agency; Dr. Martin Cetron, head of the global migration and quarantine division at the CDC; Masato Tashiro, director of Japan's National Institute of Infectious Diseases; and Russian virologist Dmitri Lvov.
    
    
15. [verwijderd] 28 september 2006 10:27

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    
    AMSTERDAM, donderdag
    In het Gerbrandypark in Geuzenveld-Slotermeer zijn gisteren acht dode vogels aangetroffen. Het betrof zeven eenden en een aalscholver.
    Wat de oorzaak is van de sterfte is nog niet bekend. Een van de vogels is nu opgestuurd voor onderzoek.
    Gerrit Zant van vogelopvang De Toevlucht kan twee oorzaken bedenken. „Of het is ’De Grote B’, oftewel botulisme of blauwalg, of wellicht toch de gevreesde vogelgriep. We zijn tot nu toe nog altijd de dans ontsprongen, maar uitsluiten kun je het niet.”
    
    Bron: De Telegraaf.
16. [verwijderd] 28 september 2006 10:30

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Lezenswaardig verhaal over de stand van zaken i.v.m. de vogelgriep:
    
    Bird flu after 22 months
    
    Category: Bird flu • Pandemic preparedness
    Posted on: September 27, 2006 7:19 AM, by revere
    
    When we first began to cover the bird flu problem -- back in 2004 -- it wasn't being discussed much anywhere, including the blogs. We started talking about it for two main reasons. First, it seemed to us, as it seemed to many informed public health scientists, that this was a possible freight train coming down the tracks. We didn't know then (nor we know now) how far the train was, whether it would get all the way to us or how fast it would be going if it did get to us. But we could feel the vibrations on the tracks and we knew enough about train wrecks of the past to worry. That was the first reason.
    
    The second reason is more complex. For us, the response (or lack of response) to the genuine possibility of a pandemic of influenza from an avian subtype that had already shown itself capable of infecting humans to deadly effect, was a grotesque metaphor for failed public health leadership, both in our on country (the US) and most everywhere else. The US CDC was preoccupied with a phantom bioterrorism threat and remodeling the agency and US public health in general to respond to the Bush administration message: "be afraid, be very afraid."
    
    CDC Director Gerberding's complicity in this will be her shameful legacy at CDC (along with a wrecked agency). Her "staying on message" delayed by at least a year, maybe two, the need to send a signal to state and local public health authorities that it was time to get busy planning. A signal was needed because state and local officials were struggling to keep their heads above water after a tax cutting frenzy had weakened routine public health. Every day was a battle to put out fires and rescue the sick and weak. Planning for a pandemic was not on the agenda, and CDC didn't put it on the agenda for them. CDC's disbursal of "bioterrorism funds" did more damage by distorting public health and in general making us less safe (see our post here. This was the counterpart to the Bush administration Iraq debacle, which we now know even their own intelligence establishment is saying has made us less safe.
    
    Now it's almost two years later and the bird flu train has not arrived. But the tracks are vibrating more strongly, we can hear the engine noise more loudly and we know the train is in the vicinity, crashing through half the world's poultry flocks, flicking off various other mammalian host species and the occasional human (251 at last count). We know much more about the virus than we did two years ago, but some of what we have learned is that what we thought we knew was wrong. That's progress, but of a peculiar sort. Still no effective vaccine in production and no likelihood of significant quantities for several years, if then. Uncertain quantities of antivirals on hand and with uncertain efficacy. And public health systems still tottering on the edge, with social service systems weakened as well. These are gross failures of government, and those government failures are traceable to gross failures in leadership.
    
    The leadership void is in every sector, including my own, academia. There are notable exceptions. Dr. Michael Osterholm of the Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota warned us early, often and persistently, and he continues to do so. But many flu scientists have continued business as usual in a setting that is anything but usual. Sharing of information, including isolates and sequences, has improved (under pressure it must be said) but there is still a long way to go. Dr. Ilaria Capua of Italy has shown genuine leadership in this area, but it has not been an easy sell. Overall, I am not proud of leadership in academic science.
    
    Government? WHO has had its ups and downs. They've made many mistakes which have damaged their credibility, its most precious asset. Now they need a new Director General and most of think they are going to screw this one up, selecting a diplomatic "go along to get along" type instead of one willing to break some china. They are still centrally important and we need to strengthen the hands of the best in the agency by our support and criticize the worst. The record of the US has been mixed. Health and Human Services Secretary Leavitt has done the right thing by going to all the fifty states to rally them to the need to prepare. But the administration he is part of, and the party in power that supports it, has done incredibly little to provide the resources to get ready. Worse, as noted above, they have hurt us. There has been some genuine progress on the local and community planning front. Not the "plans," most of which are probably worthless, but the process of getting together, talking, mobilizing the community. Baby steps, but steps nonetheless. And even the small amount that has been done will pay off handsomely if the balloon goes up.
    
    The conventional print and broadcast media are also a mixed bag. Some really terrific flu reporters have emerged, the standout by any measure being Helen Branswell of Canadian Press. She has been joined by others such as John Lauerman at Bloomberg, Maggie Fox at Reuters, Nick Zamiska at the Wall Street Journal, Declan Butler at Nature and a few more who write about the subject occasionally but well for some of the large news outlets. For the most part, though, the reporting has been terrible. Superficial, often inaccurate, just repackaging of official press releases or repetition of clearly false mantras. The broadcast media are largely absent. Worse than terrible.
    
    Then there's the internet. The official sources have their sites, of varying quality but they are usually not very timely. Plain vanilla. The real flavorful ones come from the active flu blogs and wikis, chief among them (I'm prejudiced, of course) The Flu Wiki. Started in June 2005 as an experiment in community participation in pandemic readiness it has grown to a sizeable venue with two separate parts, an active Forum or Discussion section, that buzzes with the latest news, analysis and speculation; and a resources section (the wiki proper) that has links, original postings and resources of all kinds. This site is not a bird flu site, per se. It is a public health blog, but we have done quite a lot of bird flu here because of our broader interest in public health leadership and how citizens can participate in and make public health better. Along with our wiki partners DemFromCt and Melanie Mattson we started The Flu Wiki in 2005. Those two, joined by our tech guru pogge and our colleague, moderator and friend, anon22, now do the heavy lifting. I am more a shadowy figure in the background but keep a hand in policy decisions with my colleagues.
    
    zie vervolg

    Bijlage:
17. [verwijderd] 28 september 2006 10:34

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Then there's the internet. The official sources have their sites, of varying quality but they are usually not very timely. Plain vanilla. The real flavorful ones come from the active flu blogs and wikis, chief among them (I'm prejudiced, of course) The Flu Wiki. Started in June 2005 as an experiment in community participation in pandemic readiness it has grown to a sizeable venue with two separate parts, an active Forum or Discussion section, that buzzes with the latest news, analysis and speculation; and a resources section (the wiki proper) that has links, original postings and resources of all kinds. This site is not a bird flu site, per se. It is a public health blog, but we have done quite a lot of bird flu here because of our broader interest in public health leadership and how citizens can participate in and make public health better. Along with our wiki partners DemFromCt and Melanie Mattson we started The Flu Wiki in 2005. Those two, joined by our tech guru pogge and our colleague, moderator and friend, anon22, now do the heavy lifting. I am more a shadowy figure in the background but keep a hand in policy decisions with my colleagues.
    
    In addition there are numerous flu forums, each with its own small community and character. Feisty, cantankerous, informative, maddening, exhilarating. Something for everyone but also not to everyone's tastes. And there are the blogs. There are quite a few now in FluBlogia (the term for the flu-oriented sites of the blogosphere) and I will risk hurting the feelings of some really excellent sites by mentioning only two, Crawford Killian's H5N1 (crof's blog) and The Coming Influenza Pandemic. These functions primarily as newsfilters, combing the net for bird flu news and commentary of interest and providing the links with some excerpts and some brief comment. If you look at our left sidebar you'll see a bunch of other great sites in our blogroll. Try them. Many people also like to see what's up at Henry Niman's company site, Recombinomics. It's not a blog, because comment isn't allowed, but Henry has his own special take on things and a loyal following. Again, I'm prejudiced, but I view the internet as the most significant development in the collection and dissemination of pandemic flu related news in the last two years. By far.
    
    This site, despite its interest in the bird flu problem, isn't a news filter, leaving that to others. In the early days we reported every case, but that's not needed now because others do it exceptionally well. We usually hang back for a bit to take the measure, hoping that our commentary and observations add some value to a raw reporting of developments. We think this is even more necessary now, two years down the line, because it is harder and harder to see the big picture.
    
    And what is the big picture? Here's a picture, at least, a slightly updated version of the same graph we put up last week:
    
    (zie bijlage plaatje vorige posting)
    
    This shows three flu seasons, starting in late 2003 - 2004, 2004 - 2005 and now 2005 - 2006. The first has a big but narrow spike in southeast asia. Then there is a small gap, a few sporadic cases in the summer and a second season, also southeast asia. This time the bump is wider because of more cases. From now on there are no gaps. Every month has brough us at least one human case. In the summer of 2005 we see the geographic spread represented by the different colors, chiefly Indonesia. This is a new clade or lineage of the virus that has spread out of asia. The 2005 -2006 hump is significantly wider still. As we head into the new flu season, 2006 has already surpassed 2005 in new cases (97 in 2005, 102 and counting in 2006) and we still have more than three months to go.
    
    There has also been evidence for some time of small clusters with all the hallmarks of person to person transmission. In a few cases this has been demonstrated, but mostly we are in the dark about how people are getting sick from this virus. Exposure to infected poultry probably predominates, but there are sufficiently many cases where no exposure history has been obtained that we need to also consider other reservoirs. Person to person transmission has occurred, but so far it has been rare. Yet today comes news of yet another suspected three person cluster in Indonesia, the country where the largest cluster to date (8 cases) also occurred.
    
    So the pot still boils and we don't know what the new season will bring. We can't get off the tracks, so we should get ready to manage the consequences.
    
    scienceblogs.com/effectmeasure/2006/0...
    
    
18. [verwijderd] 28 september 2006 19:23

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Precautions discussed at bird-flu meeting
    14:40' 28/09/2006 (GMT+7)
    
    
    VietNamNet Bridge - A meeting on urgent measures against the spread of avian-flu was held by the National Steering Board for Bird Flu Control (NSBBFC) in Hanoi yesterday.
    
    
    
    The NSBBFC asked municipal authorities to stop poultry slaughtering at markets and populous areas immediately while strictly controlling the trade and transportation of poultry across the border.
    
    
    
    The NSBBFC also asked relevant agencies to quickly implement the second phase of bird flu poultry vaccination plan, scheduled for completion in October.
    
    
    
    Thirty-four provinces and cities nationwide have already completed their required 54.4 million poultry vaccinations this year.
    
    
    
    In another defensive move, Minister Cao Duc Phat instructed the veterinary department to re-inspect batches of imported vaccines in response to the Ministry of Public Security’s warnings of their poor quality.
    
    
    
    The current cold weather could pave the way for the wide spread of the avian virus, said Mr. Cao Duc Phat, minister of Agriculture and Rural Development and head of the NSBBFC.
    
    
    
    Bird flu has been recently detected in nearby nations and the number of human transmissions of the disease is increasing gradually.
    
    
    
    Avian outbreaks are cyclical, usually detected in October every year.
    
    
    
    No bird flu outbreak has been found in the past nine months.
    
    
    
    (Source: SGGP)
    
    
19. [verwijderd] 28 september 2006 19:53

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    voor het archief..
    Sanofi breaks ground in cell culture-based vaccine production
    
    By Gregory Roumeliotis
    
    www.in-pharmatechnologist.com/news/ng...
    
    
    Get the latest Market Reports on
    Sanofi Pasteur
    Crucell
    cell culture
    influenza
    
    Related News
    
    MedImmune in $250m biologics plant expansion
    Consumables and contract manufacturing the drivers of the bioprocessing industry
    Vaccine manufacturers in $1bn bird flu bonanza
    Crucell/DSM push PER.C6 technology forward
    
    All news for September 2006
    All news for August 2006
    
    
    28/09/2006 - With the first clinical trial of its cell culture-based seasonal influenza vaccine commencing in the US, Sanofi Pasteur has demonstrated the production scale potential of a cell line in a successful bioreactor run of 20,000L.
    
    If successful, this new cell culture technology, licensed from Dutch biotech Crucell, will allow Sanofi Pasteur to reduce dependence on eggs while offering an additional reliable vaccine manufacturing technology.
    The scale up and the clinical trial conducted are part of a contract awarded by the US Department of Health and Human Services (HHS) to accelerate the development of a new cell culture-based influenza vaccine.
    
    According to the World Health Organisation (WHO), 5 to 15 per cent of the population is affected with upper respiratory tract infections in annual influenza epidemics.
    
    Most influenza vaccines are currently produced using embryonated chicken eggs, so there is value to improving the timely production of new vaccines in large quantities to combat a potential future influenza pandemic.
    
    Crucell's novel PER.C6 technology uses cell culture for the large-scale production of recombinant proteins and monoclonal antibodies, including influenza vaccine, where the virus is grown on specially selected cell lines instead of chicken eggs.
    
    The strengths of the PER.C6 technology lie in its safety profile, scalability and productivity under serum-free culture conditions.
    
    Crucell's PER.C6 cell line is derived from a single, human retina-derived cell, which was purposely immortalised using recombinant DNA technology.
    
    As a result, PER.C6 cells can replicate indefinitely, allowing them to be cultured in single cell suspension under serum-free conditions in quantities appropriate for large-scale manufacturing.
    
    Besides eliminating the need for chicken eggs, the cell culture process has the potential to reduce from four weeks to two or three weeks the start-up time for manufacturing once the virus strain has been identified, resulting in a more predictable manufacturing process.
    
    This scale-up process for the flu vaccine was achieved under a subcontracting agreement between Sanofi Pasteur and Lonza Biologics.
    
    Meanwhile, the clinical study Sanofi is conducting is the first step toward it filing a Biologics License Application (BLA) for a cell culture-based trivalent split inactivated seasonal influenza vaccine with the US Food and Drug Administration (FDA).
    
    The phase I trial will be conducted on 100 healthy adults, 18-64 years of age, with half of them receiving the cell-based vaccine and the other half a traditional egg-based control vaccine.
    
    Apart from influenza, Crucell's PER.C6 technology is being used in programmes for the development of vaccines against Ebola, malaria and West Nile disease.
    
20. voda 29 september 2006 16:29

    auteur info

    • voda

      Lid sinds: 02 dec 2005

      Laatste bezoek: 10 mrt 2025

    • Aanbevelingen

      Ontvangen: 93576

      Gegeven: 22921

    •    Aantal posts: 384.633

    RTRS-Intervet levert vogelgriepvaccins aan Britse boeren
    LONDEN (ANP) - Het Nederlandse bedrijf Intervet, een
    dochterbedrijf van chemieconcern Akzo Nobel, gaat Britse boeren
    van vaccins voorzien tegen vogelgriep bij onder meer kippen. Dat
    heeft het Britse ministerie van landbouw vrijdag bekendgemaakt.
    
    Intervet heeft opdracht gekregen voor de levering van tien
    miljoen doses. Hoeveel het bedrijf uit Boxmeer met de order
    verdient, is niet bekend. Intervet is 's werelds grootste
    producent van vaccins voor dieren.
    
    ((ANP Redactie Economie, email economie(at)anp.nl, +31 20
    504 5999))
    
21. gogogoo 1 oktober 2006 12:19

    auteur info

    • gogogoo

      Lid sinds: 28 feb 2006

      Laatste bezoek: 10 aug 2023

    • Aanbevelingen

      Ontvangen: 1600

      Gegeven: 808

    •    Aantal posts: 6.042

    www.intermediair.nl/artikel.jsp?id=42...
    
    Moet je dit eens lezen.
    
    Kippeeieren.GSK....hondelever......AKZO blablabla.
    
    Sanofi komt even komt om de hoek.....
    
    Maar PER.C6 Crucell nee hoor.